11 min read
researchProtocol · 1 citations
70% less dementia. The statin data APOE4 carriers need to see
Dr. Fraser breaks down ApoB targets by genotype, the statin rotation strategy, and the one test most carriers skip.
T
· Reviewed by Dr. Kevin Tran, PharmD
Key takeaways · TL;DR
APOE4 carriers benefit more from statins than non-carriers, with Mendelian randomization showing 70% dementia reduction. Dr. Fraser recommends genotype-specific ApoB targets — as low as the teens for 4/4 carriers with high Lp(a) and vascular disease — rather than standard LDL-C panels.
Definition
A protein on every atherogenic lipoprotein particle, serving as a direct count of particles driving cardiovascular disease.
Definition
A research method using natural genetic variants as proxies for exposures to establish causal relationships without confounding.
ApoB Targets by APOE Genotype
| Genotype | ApoB Target | Adjustment |
|---|---|---|
| APOE 3/3 | ~70 mg/dL | Baseline |
| APOE 3/4 | ~60 mg/dL | -10 |
| APOE 4/4 | ~55 mg/dL | -15 |
| 4/4 + Lp(a)+ | ~35 mg/dL | -35 |
| 4/4 + Lp(a)+ + vasc | ~15 mg/dL | -55 |
References · peer-reviewed
- [1]Genetic proxies for statins and dementia riskPubMed ↗
